Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification

AimTo study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification.MethodsThis study retrospectively enrolled 279 patients who underwent radical gastrectomy from January 2012 to December 2014 at our hospital and who were diagnosed with stage III GC according to the new 8th edition of the TNM classification. The patient data that were collected included age, sex, pathological parameters, survival, lymph node ratio, neo-adjuvant chemotherapy with oxaliplatin and S-1, and operation type. The characteristics, survival, and prognostic factors of the patients were analyzed by univariate and multivariate analyses.ResultsThe median OS of the patients after curative surgery was 19months, and the 3-year survival rate (3-YSR) was 25.3%. A univariate analysis showed that tumor location (P=0.01), neo-adjuvant chemotherapy (P=0.005), pathological T stage (P=0.002), pathological N stage (P<0.001), lymph node ratio (LNR) (P<0.001), and operation type (P=0.032) were significantly associated with overall survival. A multivariate analysis revealed that neo-adjuvant chemotherapy (P=0.009), pathological T stage (P=0.012), and LNR (P<0.001) were independent prognostic factors.ConclusionsNeo-adjuvant chemotherapy, pathological T stage, and LNR were independent prognostic factors for the overall survival of patients with stage III GC. The neo-adjuvant chemotherapy with oxaliplatin and S-1 can be used for the patients to improve their survival.